The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
Open accessAbstract
Summary: Over the last three decades, the development of new genome editing techniques, such as ODM, TALENs, ZFNs and the CRISPR‐Cas system, has led to significant progress in the field of plant and animal breeding. The CRISPR‐Cas system is the most versatile genome editing tool discovered in the history of molecular biology because it can be used to alter diverse genomes (e.g. genomes from both plants and animals) including human genomes with unprecedented ease, accuracy and high efficiency. The recent development and scope of CRISPR‐Cas system have raised new regulatory challenges around the world due to moral, ethical, safety and technical concerns associated with its applications in pre‐clinical and clinical research, biomedicine and agriculture. Here, we review the art, applications and potential risks of CRISPR‐Cas system in genome editing. We also highlight the patent and ethical issues of this technology along with regulatory frameworks established by various nations to regulate CRISPR‐Cas‐modified organisms/products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“Several reports have shown off-target effects of CRISPR-Cas9 in human, mouse and rat cell lines (Anderson et al., 2018; Aryal et al., 2018; Fu et al., 2013).”
BackgroundWang, Y., Cheng, X., Shan, Q., Zhang, Y., Liu, J., Gao, C., & Qiu, J.-L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2969 · Cited by 2,072
Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424 · cited 1×
“CRISPR-Cas9 has enabled scientists to repair mutations in the cftr locus that causes cystic fibrosis in cultured intestinal stem cells from cystic fibrosis patients (Hille and Charpentier, 2016; Schwank et al., 2013).”
BackgroundDiversity, classification and evolution of CRISPR-Cas systems
Koonin, E. V., Makarova, K. S., & Zhang, F. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.008 · Cited by 1,423
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273
CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y., et al. (2015) · Protein & Cell · doi:10.1007/s13238-015-0153-5 · Cited by 1,135
Cited by
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
Nanotechnology to advance CRISPR–Cas genetic engineering of plants
Demirer, G. S., Silva, T. N., Jackson, C. T., Thomas, J. B., W. Ehrhardt, D., Rhee, S. Y., Mortimer, J. C., & Landry, M. P. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00854-y · Cited by 300
Control of human toxoplasmosis
Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G. (2021) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.11.001 · Cited by 286
The Spread of Antibiotic Resistance Genes In Vivo Model
Tao, S., Chen, H., Li, N., Wang, T., & Liang, W. (2022) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2022/3348695 · Cited by 189
González, M. N., Massa, G. A., Andersson, M., Décima Oneto, C. A., Turesson, H., Storani, L., Olsson, N., Fält, A.-S., Hofvander, P., & Feingold, S. E. (2021) · Plant Cell, Tissue and Organ Culture (PCTOC) · doi:10.1007/s11240-020-02008-9 · Cited by 44
Metadata
- Authors
- Zhang, D., Hussain, A., Manghwar, H., Xie, K., Xie, S., Zhao, S., Larkin, R. M., Qing, P., Jin, S., & Ding, F.
- Venue
- Plant Biotechnology Journal
- Publisher
- Wiley
- Published
- 2020-04-30
- Volume
- 18
- Issue
- 8
- Pages
- 1651-1669
- ISSN
- 1467-7644 (ISSN-L)
- 1467-7652
- OpenAlex
- W3015943421
- Cited by
- 233
- References
- 32
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective. https://app.cochat.ai/papers/10.1111/pbi.13383
- The paper
- Zhang, D., Hussain, A., Manghwar, H., Xie, K., Xie, S., Zhao, S., Larkin, R. M., Qing, P., Jin, S., & Ding, F. (2020). Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective. Plant Biotechnology Journal. https://doi.org/10.1111/pbi.13383
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.